Docoh
Loading...

FUSN Fusion Pharmaceuticals

Filed: 7 Jun 21, 9:29am

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 4, 2021

 

 

FUSION PHARMACEUTICALS INC.

(Exact name of registrant as specified in its charter)

 

 

 

Canada 001-39344 Not Applicable

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

270 Longwood Road South

Hamilton, Ontario, Canada, L8P 0A6

(Address of principal executive offices, including zip code)

(289) 799-0891

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trade

Symbol(s)

 

Name of each exchange

on which registered

Common shares, no par value per share FUSN The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 


Item 5.07. Submission of Matters to a Vote of Security Holders.

Fusion Pharmaceuticals Inc. (the “Company”) held its annual meeting of shareholders on June 4, 2021 (the “Annual Meeting”). At the Annual Meeting, the Company’s shareholders voted in the following manner with respect to the following proposals:

 

 1.

The election of Directors, each to serve until the 2022 annual meeting of shareholders. The final voting results were as follows:

 

Nominee  For   Against   Abstain 

Donald Bergstrom, M.D., Ph.D.

   19,607,771    0    9,418 

Pablo Cagnoni, M.D.

   19,604,489    0    12,700 

Johan Christenson, Ph.D.

   19,607,771    0    9,418 

Barbara Duncan

   17,243,747    0    2,373,442 

Steve Gannon

   19,607,711    0    9,478 

Philina Lee, Ph.D.

   19,607,672    0    9,517 

Chau Khuong

   19,607,771    0    9,418 

Heather Preston, M.D.

   19,568,069    0    49,120 

John Valliant, Ph.D.

   19,607,771    0    9,418 

 

 2.

The ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm the current fiscal year ending December 31, 2021 was approved as follows:

 

For:

   23,761,138 

Against:

   7,085 

Abstain:

   1,800 


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Fusion Pharmaceuticals Inc.
Date: June 7, 2021  By: 

/s/ Maria Stahl

   Maria Stahl
   Chief Legal Officer